TY - JOUR
T1 - Factors Associated with Insulin Resistance in Women with Migraine
T2 - A Cross-Sectional Study
AU - Gur-Ozmen, Selen
AU - Karahan-Ozcan, Ruhan
N1 - Publisher Copyright:
© 2019 American Academy of Pain Medicine. All rights reserved.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Objective: Studies have shown a relationship between insulin resistance (IR) and migraine that is more evident in some migraineurs. Long-term use of various drugs and increased risk of diverse side effects is an unavoidable reality in this population of patients. Thus, in this study, we aimed to investigate factors associated with IR in migraine and the impact of chronic usage of various drugs, which might play a part in development of IR. Design: Cross-sectional study. Setting: Gebze Fatih General Hospital, Kocaeli, Turkey. Subjects: Migraine patients (N = 150) were investigated. Methods: Weight, height, waist circumference, and blood pressure were measured. Fasting glucose, fasting insulin, glycated hemoglobin, and lipid profile were also measured. IR was selected as a dependent variable. The independent variables included age, cigarette smoking, alcohol consumption, family history of migraine, diabetes mellitus and hypertension, characteristics of pain, migraine triggers and subgroups, medication used during attack treatment, medication used as prophylactic treatment, and oral contraceptive treatment. Descriptive analysis and multivariate logistic regression were performed. Results: Central obesity (odds ratio [OR] = 7.131, 95% confidence interval [CI] = 2.451-20.741, P < 0.0001), metoclopramide treatment during an attack (OR = 3.645, 95% CI = 0.996-13.346, P = 0.041), family history of DM (OR = 3.109, 95% CI = 1.189-8.132, P = 0.035), nonsteroidal anti-inflammatory drug (NSAID) usage during an attack (OR = 2.578, 95% CI = 1.053-6.311, P = 0.043), and negative family history of hypertension (OR = 0.226, 95% CI = 0.085-0.602, P = 0.002) were significant factors for exhibiting IR in migraine. Conclusions: Our study demonstrates an association between metoclopramide and NSAID treatments and IR in migraine.
AB - Objective: Studies have shown a relationship between insulin resistance (IR) and migraine that is more evident in some migraineurs. Long-term use of various drugs and increased risk of diverse side effects is an unavoidable reality in this population of patients. Thus, in this study, we aimed to investigate factors associated with IR in migraine and the impact of chronic usage of various drugs, which might play a part in development of IR. Design: Cross-sectional study. Setting: Gebze Fatih General Hospital, Kocaeli, Turkey. Subjects: Migraine patients (N = 150) were investigated. Methods: Weight, height, waist circumference, and blood pressure were measured. Fasting glucose, fasting insulin, glycated hemoglobin, and lipid profile were also measured. IR was selected as a dependent variable. The independent variables included age, cigarette smoking, alcohol consumption, family history of migraine, diabetes mellitus and hypertension, characteristics of pain, migraine triggers and subgroups, medication used during attack treatment, medication used as prophylactic treatment, and oral contraceptive treatment. Descriptive analysis and multivariate logistic regression were performed. Results: Central obesity (odds ratio [OR] = 7.131, 95% confidence interval [CI] = 2.451-20.741, P < 0.0001), metoclopramide treatment during an attack (OR = 3.645, 95% CI = 0.996-13.346, P = 0.041), family history of DM (OR = 3.109, 95% CI = 1.189-8.132, P = 0.035), nonsteroidal anti-inflammatory drug (NSAID) usage during an attack (OR = 2.578, 95% CI = 1.053-6.311, P = 0.043), and negative family history of hypertension (OR = 0.226, 95% CI = 0.085-0.602, P = 0.002) were significant factors for exhibiting IR in migraine. Conclusions: Our study demonstrates an association between metoclopramide and NSAID treatments and IR in migraine.
KW - Insulin Resistance
KW - Metoclopramide
KW - Migraine
KW - NSAIDs
UR - http://www.scopus.com/inward/record.url?scp=85078568436&partnerID=8YFLogxK
U2 - 10.1093/pm/pnz055
DO - 10.1093/pm/pnz055
M3 - Article
C2 - 30938814
AN - SCOPUS:85078568436
SN - 1526-2375
VL - 20
SP - 2043
EP - 2050
JO - Pain Medicine (United States)
JF - Pain Medicine (United States)
IS - 10
ER -